Bristol-Myers Squibb Co

Receive alerts
Market Cap:
$76.19 billion
52 weeks high
52 weeks low

Filter by article type

Viewing results 1-25 of 64


Tough summer for BB Healthcare, but long-term fundamentals remain unchanged

Healthcare stocks have taken a beating over the past couple of months, and although disappointed, BB Healthcare Trust remains confident its investments will pay dividends over the longer-term...

4 days, 13 hours ago

Eli Lilly’s $8B bet on Loxo is a ‘vote of confidence’ for novel scientific approaches that use DNA to treat cancer

Genprex Inc CEO Rodney Varner said the deal was ‘further validation’ of the promise of cancer therapies that target specific cancer-causing genetic abnormalities...

on 01/07/2019

Baird analysts stay Neutral on biotech sector as 2019 gets underway

Vertex Pharmaceuticals, Intercept Pharmaceuticals and Aimmune Therapeutics are three biotech stocks Baird's Brian Skorney describes as diamonds in the rough...

on 01/04/2019

Biotech CEOs see Bristol-Myers' $74B acquisition of Celgene as a win

The tie-up underlines how the largest pharmaceutical companies are eager to embark on the acquisition trail to boost pipelines...

on 01/03/2019

Sareum Holdings shares soar as Hybridan spotlights read-across from big US pharma takeover deal

The small-cap broker’s analysts noted that Bristol-Myers Squibb has agreed to acquire Celgene for US$74bn, with the combined entity to have six expected near-term product launches...

on 01/03/2019

Mirati Therapeutics shares tumble on release of Phase 2 trial data for lung cancer treatment

The study was evaluating Mirati’s therapy sitravatinib in combination with Bristol-Myers Squibb’s groundbreaking drug Opdivo as a method for treating non-small cell lung cancer...

on 10/22/2018

Bristol-Myers Squibb shares fall after FDA delays approval for lung cancer therapy

The EU is also requesting more information on overall survival rates for patients in the study...

on 10/22/2018

How Genprex took an abandoned pipeline drug and turned it into Oncoprex, an innovative treatment for non-small cell lung cancer

The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual...

on 10/17/2018

Bristol-Myers Squibb makes $12 million investment in Compugen, sets up research partnership

New trials will evaluate the safety and tolerability of Compugen’s COM701 in combination with Bristol-Myers' immune checkpoint inhibitor Opdivo in patients with advanced cancerous tumors...

on 10/11/2018

Merck's 2Q earnings beat Street with sales turbocharged by cancer drug Keytruda

Drug giant raised its full-year guidance to a range of US$4.22 and US$4.30 a share compared with US$4.16 to US$4.28 a share expected last quarter...

on 07/27/2018

Bristol-Myers Squibb's 2Q earnings beat Street on healthy sales of its blockbuster cancer drug Opdivo

The drugmaker raised its full-year forecast to between US$3.55 and US$3.65 per share, taking up the top and bottom end of its previous forecast by US$0.20 per share...

on 07/26/2018

Cancer doctors offer key takeaways from American Society of Clinical Oncology conference

Merck's lung cancer-fighting drug Keytruda has just been approved for the treatment of cervical cancer...

on 06/12/2018

Small-Cap Snapshot: Corindus inks deal to branch out to Japan, Funko investors file class-action suit

The medical-device company received approval to market its CorPath GRX system in Japan...

on 06/08/2018

Bristol Myers Squibb showcases positive results of new Phase 3 study evaluating cancer drug Opdivo

The study's results suggest Opdivo extends progression free survival in certain lung cancer patients when taken in combination with chemo and a drug called Yervoy...

on 06/04/2018

Jounce Therapeutics shares plunge on scant details about its Phase 1/2 ICONIC trial

The biotech's preliminary data evaluates its lead drug candidate JTX-2011...

on 05/17/2018

Bristol-Myers beats 1Q estimates, guides higher for full-year 2018 on drug approvals

The drug giant reported earnings of $0.94 per share on revenue of US$5.2bn. The consensus estimate from analysts was US$0.85 per share on revenue of US$5.2bn...

on 04/26/2018

Merck shares pop as its Keytruda drug results power ahead of Bristol-Myers, Roche

The immunotherapies boost patient survival rates, studies show...

on 04/16/2018

Bristol-Myers falls after Citi analyst says Pfizer not interested in buying the drugmaker

New York pharma giant is also working with Harvard researchers to develop fibrotic disease treatments ...

on 04/12/2018

Bristol-Myers Squibb’s new dosing for cancer drug Opdivo gets FDA green light

The approval is for a supplemental Biologics Licence Application which updates the Opdivo (nivolumab) dosing schedule to include 480 mg infused every four weeks...

on 03/06/2018
Industry & services

Bristol-Myers Squibb, Cirrus Logic, Arconic Inc, SYSCO and more - PRE-MARKET

We take a look at what's hot and what's not in pre-market deals in New York...

on 02/05/2018

Bristol-Myers shares on the uptick after positive lung cancer trial results and market beating fourth quarter results

Its Opdivo and Yervoy cancer drug combination showed improved progression-free survival in patients with advanced lung cancer compared to chemotherapy in a Phase III trial...

on 02/05/2018

Merck shares continue to rise after successful lung cancer trial

Results from a large-scale trial showed a combination of Merck’s Keytruda drug and an older type of chemotherapy helped newly-diagnosed cancer patients live longer and stop the disease from advancing...

on 01/17/2018

Bristol-Myers Squibb drops on surprise third quarter profits miss

Third quarter profits slumped to US$845mln or 51 cents per share from US$1.20bn or 72 cents a share in the year-earlier period...

on 10/26/2017

Halozyme Therapeutics stock to surge thanks to Bristol-Myers licensing deal

Halozyme gets US$105mln upfront plus milestone payments and a share of future revenues...

on 09/14/2017